Company intelligence / Profile preview

LyteGro

Ownership: Private
Development stage: Commercial

Overview

LyteGro has developed and commercialized BacLyte, a patented microbial growth enhancer derived from waste bananas. Their products significantly improve fermentation efficiency in industrial processes such as alcohol production, yeast/probiotic manufacturing, R&D media supplementation, and food fermentation. Trials have shown increased yields (10–20%), reduced processing times by half, and substantial resource savings. Sigma-Aldrich/Merck licenses their product for global R&D use; multiple distillers have successfully trialed their solutions with further expansion planned[1][3][4].

Modalities: Microbial growth enhancer
Industry: Non-Drug Biotech

Drug pipeline

3 assets

BacLyte

Commercial

2 more assets in the full pipeline.

Request access →

Partnerships

Sigma-Aldrich / Merck Group [4]Multiple UK distillers [1][3]Early discussions with major bioenergy companies [4]

Beyond the preview

Go deeper on LyteGro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LyteGro.

Explore the full profile